Access the full text.
Sign up today, get DeepDyve free for 14 days.
P. Cheema, S. Gavura, M. Migus, B. Godman, L. Yeung, M. Trudeau (2012)International variability in the reimbursement of cancer drugs by publically funded drug programs.
Current oncology, 19 3
P. Folino-Gallo, Simona Montilla, M. Bruzzone, N. Martini (2008)Pricing and reimbursement of pharmaceuticals in Italy
The European Journal of Health Economics, 9
Roy Berggren, Martin Møller, R. Moss, Pawel Póda, K. Śmietana (2012)Outlook for the next 5 years in drug innovation
Nature Reviews Drug Discovery, 11
B Wettermark, B Godman, K Andersson, LL Gustafsson, A Haycox, V Bertele (2008)Recent national and regional drug reforms in Sweden: implications for pharmaceutical companies in Europe
(2005)A pan-European comparison regarding patient access to oncology drugs
M. Niezen, A. Bont, E. Stolk, A. Eyck, L. Niessen, H. Stoevelaar (2007)Conditional reimbursement within the Dutch drug policy.
Health policy, 84 1
S. Vogler, C. Habl, Martina Bogut, L. Voncina (2011)Comparing pharmaceutical pricing and reimbursement policies in Croatia to the European Union Member States
Croatian Medical Journal, 52
Warren Linley, D. Hughes (2013)Societal views on NICE, cancer drugs fund and value-based pricing criteria for prioritising medicines: a cross-sectional survey of 4118 adults in Great Britain.
Health economics, 22 8
N. Grandfils (2008)Drug price setting and regulation in France
Tilo Netzer (2006)European Union centralised procedure for marketing authorisation of oncology drugs: an in-depth review of its efficiency.
European journal of cancer, 42 4
A. Degrassat-Théas, M. Bensadon, C. Rieu, M. Angalakuditi, C. Pen, P. Paubel (2012)Hospital Reimbursement Price Cap for Cancer Drugs: the French experience in controlling hospital drug expenditures
M. Malvezzi, P. Bertuccio, F. Levi, C. Vecchia, E. Negri (2013)European cancer mortality predictions for the year 2013.
Annals of oncology : official journal of the European Society for Medical Oncology, 24 3
Steven Simoens, M. Dooms (2011)How much is the life of a cancer patient worth? A pharmaco‐economic perspective
Journal of Clinical Pharmacy and Therapeutics, 36
M. Jelenc, S. Krnel, M. Seljak, T. Albreht, M. Meglic (2011)European Partnership for Action Against Cancer - EPAAC
W. Schäfer, M. Kroneman, W. Boerma, M. Berg, G. Westert, W. Devillé, E. Ginneken (2016)The Netherlands: health system review.
Health systems in transition, 12 1
A. Maynard, K. Bloor (2011)The economics of the NHS cancer drugs fund
Applied Health Economics and Health Policy, 9
B. Wettermark, B. Godman, K. Andersson, L. Gustafsson, A. Haycox, V. Bertele' (2012)Recent National and Regional Drug Reforms in Sweden
Alain Denis, Lut Mergaert, C. Fostier, I. Cleemput, S. Simoens (2010)A comparative study of European rare disease and orphan drug markets.
Health policy, 97 2-3
A. Degrassat-Théas, M. Bensadon, C. Rieu, M. Angalakuditi, C. Pen, P. Paubel (2012)Hospital Reimbursement Price Cap for Cancer Drugs
G. Apolone, R. Joppi, V. Bertele', S. Garattini (2005)Ten years of marketing approvals of anticancer drugs in Europe: regulatory policy and guidance documents need to find a balance between different pressures
British Journal of Cancer, 93
F. Ferré, A. Belvis, L. Valerio, S. Longhi, Agnese Lazzari, G. Fattore, W. Ricciardi, A. Maresso (2014)Italy: health system review.
Health systems in transition, 16 4
J. Emmerich, N. Dumarcet, Annie Lorence (2012)France's new framework for regulating off-label drug use.
The New England journal of medicine, 367 14
K. Claxton, A. Briggs, M. Buxton, A. Culyer, C. McCabe, S. Walker, M. Sculpher (2008)Value based pricing for NHS drugs: an opportunity not to be missed?
BMJ : British Medical Journal, 336
M. Malvezzi, P. Bertuccio, F. Levi, C. Vecchia, E. Negri (2012)European cancer mortality predictions for the year 2012.
Annals of oncology : official journal of the European Society for Medical Oncology, 23 4
U. Tirelli, A. Bearz (2009)Market and patient access to new oncology products in Europe: a current, multidisciplinary perspective.
Annals of oncology : official journal of the European Society for Medical Oncology, 20 8
A. Anell, A. Glenngård, S. Merkur (2012)Sweden health system review.
Health systems in transition, 14 5
M. Franken, Maïté Polain, I. Cleemput, M. Koopmanschap (2012)SIMILARITIES AND DIFFERENCES BETWEEN FIVE EUROPEAN DRUG REIMBURSEMENT SYSTEMS
International Journal of Technology Assessment in Health Care, 28
M. Drummond, A. Mason (2007)European perspective on the costs and cost-effectiveness of cancer therapies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25 2
(2011)Value-based pricing: incentive for innovation or zero net benefit
S. Boyle (2011)United Kingdom (England): Health system review.
Health systems in transition, 13 1
A. Bernardi, R. Pegoraro (2008)The ethics of off‐label use of drugs: oncology pharmacy in Italy
Journal of Clinical Pharmacy and Therapeutics, 33
(2004)financieringssystemen van ziekenhuisgeneesmiddelen: een beschrijvende studie van een aantal Europese landen en Canada
J. Carlson, L. Garrison, S. Sullivan (2009)Paying for Outcomes: Innovative Coverage and Reimbursement Schemes for Pharmaceuticals
Journal of Managed Care Pharmacy : JMCP, 15
Richard Sullivan, J. Peppercorn, Karol Sikora, John Zalcberg, Neal Meropol, Eitan Amir, David Khayat, Peter Boyle, Philippe Autier, I. Tannock, Tito Fojo, Jim Siderov, Steve Williamson, Silvia Camporesi, J. Mcvie, A. Purushotham, Peter Naredi, Alexander Eggermont, Murray Brennan, Michael Steinberg, M. Ridder, S. McCloskey, Dirk Verellen, Terence Roberts, G. Storme, Rodney Hicks, P. Ell, B. Hirsch, David Carbone, Kevin Schulman, Paul Catchpole, David Taylor, Jan Geissler, Nancy Brinker, David Meltzer, David Kerr, M. Aapro (2011)Delivering affordable cancer care in high-income countries.
The Lancet. Oncology, 12 10
A. Hågå, J. Sverre (2002)Pricing and reimbursement of pharmaceuticals in Norway
The European Journal of Health Economics, 3
(2013)A (2012) Cost containment policies in public pharamceutical spending in the EU
S. Gerkens, S. Merkur (2010)Belgium: Health system review.
Health systems in transition, 12 5
C. Pen, G. Priol, H. Lilliu (2003)What criteria for pharmaceuticals reimbursement? An empirical analysis of the evaluation of "medical service rendered" by reimbursable drugs in France.
The European journal of health economics : HEPAC : health economics in prevention and care, 4 1
M. Garau, J. Mestre-Ferrandiz (2009)Access Mechanisms for Orphan Drugs: A Comparative Study of Selected European Countries
Health Economics eJournal
C. Mullins, R. Montgomery, S. Tunis (2010)Uncertainty in assessing value of oncology treatments.
The oncologist, 15 Suppl 1
M. Collins, N. Latimer (2013)NICE’s end of life decision making scheme: impact on population health
BMJ : British Medical Journal, 346
C. Sorenson (2010)Use of comparative effectiveness research in drug coverage and pricing decisions: a six-country comparison.
Issue brief, 91
M. Michel, M. Toumi (2012)Access to orphan drugs in Europe: current and future issues
Expert Review of Pharmacoeconomics & Outcomes Research, 12
A. Tolle, W. Meyer-Sabellek (2003)Off-Label-Use
Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz, 46
A. Alwan (2011)Global status report on noncommunicable diseases 2010.
D. Felix (2012)Das Institut für das Entgeltsystem im Krankenhaus (InEK)
P. Dolan, A. Tsuchiya (2009)The social welfare function and individual responsibility: some theoretical issues and empirical evidence.
Journal of health economics, 28 1
(2010)Optimalisatie van de werkingsprocessen van het bijzonder solidariteitsfonds
K. Chalkidou, S. Tunis, R. Lopert, L. Rochaix, P. Sawicki, M. Nasser, B. Xerri (2009)Comparative effectiveness research and evidence-based health policy: experience from four countries.
The Milbank quarterly, 87 2
J. Espín, J. Rovira, Leticia García (2011)Experiences and Impact of European Risk-Sharing Schemes Focusing on Oncology Medicines
J. Collier (1986)NHS PHARMACEUTICAL PRICE REGULATION SCHEME
The Lancet, 328
M. Drummond, R. Tarricone, A. Torbica (2013)Assessing the added value of health technologies: reconciling different perspectives.
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 16 1 Suppl
C. Pen, G. Priol, H. Lilliu (2003)What criteria for pharmaceuticals reimbursement?
The European Journal of Health Economics, 4
D. Levêque (2008)Off-label use of anticancer drugs.
The Lancet. Oncology, 9 11
Asher Mullard (2011)Mediator scandal rocks French medical community
The Lancet, 377
C. Beerepoot, R. Donk, H. Hermans, J. Linders (2010)Algemene Wet Bijzondere Ziektekosten
S Gress, D Niebuhr, U May, J Wasem (2007)Reform of prescription drug reimbursement and pricing in the German social health insurance market: a comparison of three scenarios
P. Neumann, S. Bliss, J. Chambers (2012)Therapies for advanced cancers pose a special challenge for health technology assessment organizations in many countries.
Health affairs, 31 4
R. Trowman, Helen Chung, C. Longson, P. Littlejohns, Peter Clark (2011)The National Institute for Health and Clinical Excellence and Its Role in Assessing the Value of New Cancer Treatments in England and Wales
Clinical Cancer Research, 17
S. Gress, Dea Niebuhr, U. May, J. Wasem (2012)Reform of Prescription Drug Reimbursement and Pricing in the German Social Health Insurance Market
J. Adamski, B. Godman, G. Ofierska-Sujkowska, Bogusława Osińska, H. Herholz, Kamila Wendykowska, O. Laius, Saira Jan, C. Sermet, Corrine Zara, Marija Kalaba, Roland Gustafsson, K. Garuolienė, A. Haycox, S. Garattini, L. Gustafsson (2010)Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers
BMC Health Services Research, 10
R. Lerose, P. Musto, M. Aieta, C. Papa, A. Tartarone (2011)Off-label use of anti-cancer drugs between clinical practice and research: the Italian experience
European Journal of Clinical Pharmacology, 68
Public health systems need to make well-founded choices in order to distribute their scarce resources in the most efficient way. Given the number of cancer patients, public/private investments in oncology research, the growing number of new anti-cancer agents and consequent budget impact of cancer care, market access of cancer drugs has become delicate over the last decade. Furthermore, decision makers are challenged by ethical objections and endeavour to provide fair and equal access to treatments for cancer patients. The aim of this study is to generate an overview of market access procedures for cancer drugs in eight European countries and formulate advice for improvement of resource allocation. Results are obtained through a literature review and a qualitative questionnaire and validated by experts with proven knowledge about procedures for price setting and reimbursement of drugs. Diverse measures are applied in the studied countries to optimize reimbursement of cancer drugs such as adjusted cost-effectiveness threshold, regulations for off-label use and new market access agreements. Additionally, innovative cancer drugs are excluded from explicit cost control measures such as payback of budget excess by pharmaceutical companies and lump-sum payments per diagnostic related groups (DRG) in the hospital. The results suggest that cancer is prioritized above other disease areas. Further research is necessary to address the question if society attaches higher value to cancer drugs than to treatments for other diseases.
Targeted Oncology – Springer Journals
Published: Nov 19, 2013
Access the full text.
Sign up today, get DeepDyve free for 14 days.